If you haven't already I would encourage you to listen to x.com/BiotechCH/stat… from today, AF's comments regarding self-policing are spot-on Bad actors like DI aren't bad for just their own company, it's a contagion for all of biotech.

I’m sorry Sarepta Therapeutics, this is just wrong! IMO, our industry must always put patients first and we must be transparent to secure public and stakeholder trust. We also must hold each other accountable.

If Sarepta doesn't reform itself by Monday, and if the biotech industry is serious about 1) doing the right thing and 2) preserving public trust, this should happen: 1) Roche should publicly denounce its partner's decisions. 2) Biotechnology Innovation Organization should kick Sarepta out of BIO.

Omega Funds matches size of 2021 fund with $647M for life sciences startups; endpoints.news/omega-funds-ma… Otello

1/Here’s an excellent Financial Times article which accurately describes the problematic situation which many big Pharma companies such as $PFE $JNJ $BMY $ABBV $LLY $MRK $SNY and others are now facing - the upcoming patent cliff scenario. With IP rights which are about to expire

Breaking news: Otello just raised Omega fund 8, closing at $647M, same as fund 7. Significant part to be invested in 🇪🇺🤑

Evotec shares drop sharply after lowering 2025 revenue forecast for 2025 to €800M. ih.advfn.com/market-news/ar…

Obesity may come in 11 different types, each with their own cause which may benefit from different treatments and prevention strategies newscientist.com/article/248874…

Sanofi $SNY to buy vaccine biotech Vicebio for $1.15B upfront statnews.com/2025/07/22/san… via Andrew Joseph

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing. Full video: biotechtv.com/post/avalyn-ph…

A statement regarding The Wall Street Journal

Avalyn pulls in $100M to challenge oral lung fibrosis drugs with inhaled rivals firstwordpharma.com/story/5982858

Abivax $ABVX shares up over 550% as ulcerative colitis drug scores two Phase 3 wins! endpoints.news/abivax-shares-…

Rich Law So outstanding and well deserved!! CEO Marc de Garidel was on the show end of 2023: youtube.com/watch?v=njZR8u… Glad I bought stock after the interview. Will compensate for Evotec losses 😇

Wow – this could become (I think) the first miRNA therapeutic It increases miR‑124 levels – mainly in immune cells miR‑124, in turn, prevents the translation of a range of of inflammatory proteins (STAT3 and IL6R – T cells and MCP‑1 /CCL2 – macrophages)

More info here! ir.abivax.com/news-releases/…

So Adam Feuerstein ✡️ says $SRPT may not survive, and I think his argument is crisp and cogent.   statnews.com/2025/07/24/sar…

Today, we take the next step in Verve’s journey: the acquisition by Eli Lilly and Company is now complete. From the founding of Verve in 2018 to this milestone in 2025, we have worked with urgency and conviction to advance a bold idea — that a single-course gene editing medicine could

Buoyed by a string of exits, Omega Funds expects few changes to its investment strategy as it deploys its new $647M eighth fund buff.ly/WhgPQkj

Wow